Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of DWC202313 and DWC202314 in Healthy Volunteers
NCT06119958Phase 1Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olmesartan, amlodipine and indapamide in hypertension (HTN) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State up to 14 days and Area Under the Plasma Concentration-Time Curve to Last Timepoint at Steady State up to 14 days. Started Oct 2023; status: recruiting.
02
Drugs
olmesartanamlodipineindapamide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06119958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06119958.